Freedom Lumbar Disc in the Treatment of Lumbar Degenerative Disc Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-09-30

Study Completion Date

2018-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will look at the result of using the FLD device as an artificial lumbar disc. The study will compare the safety and effectiveness of the FLD artificial lumbar disc to an already approved artificial lumbar disc.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Freedom® Cervical Disc Use In The Treatment of Cervical Degenerative Disc Disease

NCT01763619

Symptomatic Cervical Degenerative Disc Disease (DDD) From C3-C7

UNKNOWN NA

Activ-L™ Artificial Disc Treatment of Degenerative Disc Disease in the Treatment of Degenerative Disc Disease

NCT00589797

Degenerative Disc Disease

COMPLETED NA

Study of the Safety and Effectiveness of the Artificial Cervical Disc - Low Profile Device at Two Adjacent Levels

NCT00637156

Cervical Degenerative Disc Disease Radiculopathy Myelopathy

COMPLETED NA

Study of Safety & Effectiveness of PRESTIGE® LP Cervical Disc vs. Anterior Cervical Fusion in Cervical DDD

NCT00667459

Cervical Degenerative Disc Disease

COMPLETED PHASE3

Lumbar Degenerative Disc Disease Treated With Anterior Tension Band System (ATB) With ALIF/FRA Spacer

NCT01323387

Lumbar Degenerative Disc Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Freedom Lumbar Disc is indicated for spinal arthroplasty in skeletally mature patients with single level, symptomatic degenerative disc disease (DDD) from L3-S1. This is a prospective, multi-center, randomized, controlled trial. Subjects with DDD will be randomized to disc arthroplasty with the FLD device or a control device. The overall purpose (objective) of this trial is to collect clinical data to demonstrate the safety and effectiveness of FLD used for the treatment of symptomatic lumbar degenerative disc disease compared to the control device.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Degenerative Disc Disease (DDD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment

FLD

Group Type EXPERIMENTAL

FLD

Intervention Type DEVICE

Artificial lumbar disc

Control

Group Type ACTIVE_COMPARATOR

Control

Intervention Type DEVICE

Artificial lumbar disc

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FLD

Artificial lumbar disc

Intervention Type DEVICE

Control

Artificial lumbar disc

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Single level, degenerative disc disease at L3 to S1, inclusive.
* Minimum of 6 months of unsuccessful conservative treatment.
* Subject is a surgical candidate for an anterior approach to the lumbar spine (\<3 abdominal surgeries).
* Back pain at the operative level only (by discogram, if necessary).
* Leg pain and/or back pain due to disc space settling, with or without radicular symptoms related to foraminal narrowing.
* Subject must understand and sign the written Informed Consent.

Exclusion Criteria

* Prior fusion at any lumbar level.
* Clinical evidence of adjacent lumbar segment disease.
* Previous trauma to the L3, L4, L5, or S1 levels (in compression or burst).
* Non-contained or extruded herniated nucleus pulposus.
* Congenital stenosis or central/lateral stenosis (mid-sagittal stenosis of \<8mm by CT or MR) secondary to acquired degenerative disease requiring treatment that destabilizes the spine (requiring fusion), or for subjects in whom increased motion may increase symptoms.
* Retro- or spondylolisthesis of ≥ 2.5 mm which is either fixed or present on flexion/extension films, and slippage of vertebral body where the listhesis is due to disc space settling in the absence of degenerative facets or a pars interarticularis defect.
* Significant kyphosis (\>11ْ sagittal plane deformity).
* History of any invasive malignancy (except non-melanoma skin cancer) unless treated with curative intent and there have been no clinical signs or symptoms of malignancy for at least 5 years (in particular, spinal tumors).
* Acute or chronic infection (local or systemic).
* Instability or facet joint arthrosis, clinically significant.
* Arachnoiditis.
* Known or suspected allergy to titanium, polyurethane, cobalt, chromium, molybdenum or silicone.
* Radiographic findings of a fused or total collapsed disc.
* Subject using medications or drugs known to potentially interfere with bone or soft tissue healing (high-dose of steroids, osteoclast inhibitors, etc.).
* Systemic disease affecting the spine, including rheumatoid arthritis, autoimmune disease, AIDS, HIV, or hepatitis.
* Paget's disease, osteomalacia or any other metabolic bone disease (excluding osteoporosis which is addressed separately).
* Psychosocial disorders (e.g. evidence or drug or alcohol abuse).
* Morbid (extreme) obesity (BMI ≥ 40 kg/m2).
* Bone growth stimulator use in spine.
* Investigational drug or device use within 30 days.
* Osteoporosis or osteopenia or metabolic bone disease as confirmed by DEXA scan if poor bone quality is suspected (T-score \< -1.0).
* If female of childbearing potential, pregnant or interested in becoming pregnant in the next three years.
* Type 1 diabetes, and uncontrolled (or poorly controlled) Type 2 diabetes.
* Subjects with a history of implant rejection.
* Provocative discography with non-concordant pain at the operative level.
* Incarcerated subjects.
* Myelopathy.
* Significant leg pain of a radicular or neurogenic claudication nature.
* Involved vertebral endplates dimensionally smaller then 39 mm in the mediallateral and/or 32 mm in the anterior-posterior directions.
* Subjects not able to meet follow-up requirements.
* Lumbar scoliosis \> 11 degrees.
* Any previous or current litigation related to the spine.

Minimum Eligible Age

21 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No